百洋医药：9月17日召开董事会会议

Group 1 - The core viewpoint of the article is that Baiyang Pharmaceutical held its fourth board meeting on September 17, 2025, to discuss the appointment of a securities affairs representative and other related documents [1] - For the fiscal year 2024, Baiyang Pharmaceutical's revenue composition is as follows: 92.5% from sales of pharmaceuticals and medical devices, 7.18% from brand services, and 0.32% from other businesses [1] - As of the time of reporting, Baiyang Pharmaceutical has a market capitalization of 15.9 billion yuan [1]